The purpose of this study was to evaluate fluorescence in situ hybridization abnormalities of the 2p23 anaplastic lymphoma kinase (ALK) gene loci in lymphomas with anaplastic morphology. We studied 24 anaplastic large cell lymphomas (ALCL) classified by World Health Organization criteria [17 primary nodal/ systemic (10 ALK þ , 7 ALKÀ), seven primary cutaneous], and 17 additional non-Hodgkin's lymphomas [one ALK þ B-lineage lymphoma, 14 ALKÀ diffuse large B-cell lymphomas (seven anaplastic variants, five nonanaplastic, two secondary CD30 þ ), two follicular lymphomas]. ALKÀ lymphomas with anaplastic morphology showed extra nonrearranged anaplastic lymphoma kinase gene loci (P ¼ 0.004) due to trisomy 2 irrespective of the following factors: B or T/null phenotype (P ¼ 0.315), diagnostic categories of systemic or cutaneous ALCL or the above-mentioned B-cell lymphomas (P ¼ 0.131), and CD30 positivity by immunohistochemistry (P ¼ 1.000). Trisomy 2 was absent in all ALK þ lymphomas (P ¼ 0.009), which showed rearranged ALK gene loci (Po0.001). Whether trisomy 2 is a primary or secondary event that leads to ALKÀ lymphomas cannot be determined from this study. Its presence in secondary B-cell lymphomas suggests that trisomy 2 may be a secondary cytogenetic aberration in lymphomas in general. Further investigation of this finding is necessary to further our understanding of the heterogeneous group of ALKÀ lymphomas.
Anaplastic large cell lymphomas (ALCL) were originally described 1 as a large cell lymphoma with a characteristic cytomorphology and preferential paracortical and intrasinusoidal involvement of lymph nodes, in which virtually all neoplastic cells were strongly positive for the Ki-1 (CD30) antibody. Since then, a number of morphologic variants have been described. [2] [3] [4] [5] [6] [7] [8] [9] Clinically, ALCL include primary systemic ALCL, primary cutaneous ALCL, HIVrelated ALCL, or forms secondary to another lymphoproliferative disorder. 10, 11 According to the Revised European-American and World Health Organization (WHO) classifications of lymphoid neoplasms, the diagnosis of ALCL is restricted to T/null-cell lymphomas, 12 the majority of which express the anaplastic lymphoma kinase (ALK) protein and demonstrate clonal rearrangement of the T-cell receptor genes. 13 Primary systemic ALCL include ALK þ and ALKÀ cases, with ALK þ cases comprising a distinct entity with favorable prognostic significance. [13] [14] [15] [16] Whether ALKÀ ALCL cases are a variant of ALK þ ALCL or a different clinicopathologic entity is not clear at this time. 13 Anaplastic large B-cell lymphomas, as recognized by the Kiel classification, 17 are considered to be an anaplastic variant of diffuse large B-cell lymphomas. 13, 18 Rare ALK þ diffuse large B-lineage lymphomas have also been described, 19 and shown to have 2p23 anaplastic lymphoma kinase gene (ALK) translocations, [20] [21] [22] similar to those present in ALCL. [23] [24] [25] [26] The purpose of this study was to examine the 2p23 ALK loci by fluorescence in situ hybridization (FISH) on paraffin-embedded sections of ALK þ and ALKÀ lymphomas with anaplastic morphology, including cases classified as ALCL and non-ALCL by WHO criteria. We identified extra copies of nonrearranged 2p23 ALK loci as a novel recurring chromosomal aberration in ALKÀ lymphomas with anaplastic morphology, including ALCL and non-ALCL, suggesting a common pathogenetic pathway in the heterogeneous group of ALKÀ lymphomas.
Materials and methods

Cases (ALCL and Non-ALCL)
The surgical pathology database at Roswell Park Cancer Institute was searched for ALCL and ALK þ lymphomas. Cases included on the basis of histopathologic features and CD30 positivity, as originally described by Stein et al 1 were reclassified according to WHO criteria. The following 24 ALCL cases were included: 15 primary systemic nodal/ extranodal ALCL (10 ALK þ , five ALKÀ) in 15 patients (three pediatric and 12 adults; nine males and six females; 11 nodal and four extranodal: lung, small bowel, bone and soft tissue), two recurrences of ALKÀ primary systemic ALCL, and seven cutaneous ALCL in six adult patients (five males, one female). The cutaneous ALCL cases included two recurrences. The histopathology of the majority of cases of primary systemic nodal/extranodal ALCL was typical for the common variant of ALCL, likely a reflection of our study design for case retrieval. Our ALK þ cases included a majority (n ¼ 6) with sole cytoplasmic ALK positivity, and four with both cytoplasmic and nuclear positivity. All cutaneous ALCL cases showed histologic features consistent with ALCL, that is, sheets of large lymphoma cells infiltrating the dermis, with subcutaneous fat involvement. The primary systemic ALCL cases did not have a prior clinical history of a lymphoproliferative disorder by review of the patients' medical records. The cases of primary cutaneous ALCL did not have a history of any systemic/nodal disease for 1 year after diagnosis by clinical or radiologic examination. Most of our cases were referred from other institutions.
The non-ALCL cases included one ALK þ nodal diffuse large B-lineage lymphoma and 17 ALKÀ lymphomas [14 diffuse large B-cell lymphomas in 14 patients (five CD30 þ and two CD30À cases with anaplastic histologic features, five nonanaplastic, two secondary CD30 þ composite lymphomas), two follicular lymphomas, and the primary component within one of the above-mentioned composite lymphomas]. The composite lymphomas included one diffuse large B-cell lymphoma, anaplastic variant coexistent with follicular lymphoma, grade 1, and one large B-cell lymphoma with nodular lymphocyte predominant Hodgkin lymphoma. 27, 28 The nodular Hodgkin component in the latter case was available for FISH study, while the paraffin block corresponding to the primary component in the other composite case was not available for study.
The diagnostic hematoxylin and eosin (H&E) stained and immunohistochemical-stained sections were reviewed in all cases (RK, MB). The cases of primary cutaneous ALCL were also reviewed by our dermatopathologist (RTC). Paraffin section immunohistochemical stains performed using either the Ventana ES or DAKO autostainer included CD3 (polyclonal), CD4 (clone 1F6), CD5 (clone CD5/54/ F6), CD7 (clone 8H8.1), CD8 (clone C8/144B), CD15 (clones DTD7 and BC97), CD20 (clone L26), CD30 (clone Ber-H2), CD45RO (clone UCHL-1), CD79a (clone HM57), EMA (clone E29), ALK1 (clone ALK1), and the cytotoxic cell-associated markers TIA-1 (clone TIA-1) and Granzyme B (clone GrB-7). Stains for CD138 (clone MI15), IgM (polyclonal), IgG (polyclonal), IgA (polyclonal), and k (polyclonal) and l (polyclonal) immunoglobulins were performed in the case of ALK þ diffuse large B-lineage lymphoma. All antibodies were obtained from DAKO (Carpinteria, CA, USA), except for CD30, CD15, TIA-1 (Biocare Medical, Walnut Creek, CA, USA), CD4 (Novocastra, Vector Laboratories, Burlingame, CA, USA), CD7 (Immunotech, Inc., Westbrook, ME, USA), and GrB-7 (Serotec Ltd, Raleigh, meric 250 kb SpectrumOrange and centromeric 300 kb SpectrumGreen probes) and detects 2p23 ALK gene rearrangements, including variant translocations involving the same 2p23 breakpoint as in the t(2;5)(p23;q35) translocation. In cases that showed numerical abnormalities of the nonrearranged 2p23 ALK gene loci, additional FISH studies were performed using alpha satellite centromeric probes for chromosomes 2 and 10 (Vysis, Inc.). The probe for chromosome 10 was used as a control for evaluation for polyploidy, since trisomy 10 appears not to be commonly associated with the pathogenesis of lymphomas. Since the 2p23 locus-specific probe also detects aneusomy of chromosome 2, the centromeric probes were not used in the cases with normal numbers of nonrearranged 2p23 loci. Sections from randomly selected small benign lymph nodes from two nonlymphoma patients and two ALCL study cases served as external negative FISH controls. Normal skin and small bowel epithelium served as negative internal FISH controls in the applicable cases. The tissue sections were deparaffinized in a xylene substitute (Hemo De, Fisher Scientific), and prepared for FISH using a paraffin pretreatment reagent kit (Vysis, Inc.), as per the manufacturer's instructions. Subsequently, the probe and target DNA were codenaturated at 851C for 1 min, using the Hybrite system (Vysis, Inc.), and then hybridized at 371C for 18-20 h. The posthybridization washes were performed at 73711C for 2 min in 0.4 Â salinesodium citrate buffer (SSC)/0.3% octylphenoxy polyethoxy ethanol (Nonidet P-40), followed by 2X SSC/0.1% Nonidet P-40 at room temperature for 1 min. The sections were counterstained with 4 0 ,6-diamidino-2-phenylindole dihydrochloride (DAPI II, 125 ng/ml, Vysis, Inc.) and then analyzed on a Nikon Optiphot-2 epifluorescence microscope (Nikon, Melville, NY, USA). The adequacy of hybridization was evaluated by examining the entire section, and representative lymphoma foci were identified for study by correlating with the corresponding H&E sections. At least 20 high-power fields ( Â 1500, oil) were studied using single, dual and triple bandpass filters (DAPI, SpectrumGreen, SpectrumOrange, Vysis, Inc.) in areas with minimal nuclear overlap. At least 500 nuclei with strong and well-delineated hybridization signals were examined by two observers (RK, SNJS). A set of immediately adjacent or fused orange/green signals was interpreted as a normal, non-rearranged 2p23 ALK gene locus. Digitized images were captured using a monochrome CCD camera (Cohu Inc., San Diego, CA, USA) and image analysis software (MacProbe, Perceptive Scientific Instruments, Inc., League City, TX, USA).
Statistical Analysis
, B-vs T/null cell phenotype, the WHO diagnostic categories of ALCL, cutaneous ALCL, diffuse large B-cell lymphoma (anaplastic variants and nonanaplastic) and follicular lymphoma, CD30 positivity, ALK1 positivity by immunohistochemistry and the sex of the patient. All P-values are two-sided and correspond to Fisher's exact test, wherever applicable. A P-value of less than 0.05 was considered statistically significant.
Results
FISH
FISH was successful in 18 ALCL and 17 non-ALCL cases. A summary of the FISH findings in all study groups is presented in Table 2 .
Primary systemic ALCL (ALK þ and ALKÀ) Rearranged 2p23 ALK gene loci were present in biopsies from all (n ¼ 6) ALK þ ALCL patients (Figure 3a) . Further, in two of these six cases, two extra 3 0 telomeric ends of the rearranged 2p23 locus were noted, suggesting the presence of a secondary cytogenetic aberration.
There was no rearrangement of the 2p23 ALK gene locus in the primary systemic ALKÀ ALCL cases (n ¼ 5). However, there were extra nonrearranged 2p23 loci (Figure 3b ) due to extra copies of chromosome 2 within the lymphoma cells, as confirmed by using centromeric probes for chromosomes 2 ( Figure 3c ) and 10 in four cases with additional available sections. In all five cases, 40-80% of the lymphoma cells had one extra nonrearranged 2p23 signal. Two cases showed additional 3-9 nonrearranged 2p23 signals in 1-5% lymphoma cells. Of interest, two biopsies from one patient over a 4-month interval showed virtually identical findings (one extra nonrearranged 2p23 locus) at both times.
Primary cutaneous ALCL
There was no rearrangement of the 2p23 ALK gene locus in the cutaneous ALCL cases (n ¼ 7). However, in five cases, one extra nonrearranged 2p23 signal was detected in 15-25% of the lymphoma cells. Both the biopsies from one patient showed similar FISH findings (one extra nonrearranged 2p23 locus). Owing to the small diagnostic biopsies and depleted tissue in the sections studied by centromeric FISH probes, we could not confirm trisomy 2 by centromeric probes in the cutaneous ALCL cases.
ALK þ diffuse large B-lineage lymphoma The 2p23 ALK gene locus was rearranged in greater than 90% of the lymphoma cells in this one case (Figure 3d ).
Non-ALCL ALK-negative lymphomas and controls
All ALKÀ non-ALCL cases and controls were negative for 2p23 ALK gene locus rearrangement.
However, extra copies of non-rearranged 2p23 loci were detected in lymphoma cells of 66% (n ¼ 9) of ALKÀ diffuse large B-cell lymphomas with anaplastic morphology (2/5 CD30 þ and 2/2 CD30À anaplastic variants, and 2/2 secondary CD30 þ ).
Extra nonrearranged 2p23 loci signals (1-3) due to extra copies of chromosome 2 were detected in about 20-40% of lymphoma cells in both of the CD30 þ ALKÀ diffuse large B-cell lymphoma, anaplastic variant cases. One of these two cases was HIV-associated; this case showed trisomy 10 in addition to trisomy 2, indicating a hyperdiploid karyotype of the lymphoma cells. One extra nonrearranged 2p23 locus due to trisomy 2 was detected in about 10-20% of lymphoma cells in both of the CD30À diffuse large B-cell lymphoma cases with anaplastic histologic features, while the number of nonrearranged 2p23 ALK loci signals was normal in all nonanaplastic diffuse large B-cell lymphoma cases (n ¼ 5).
Extra nonrearranged 2p23 loci due to trisomy 2 were detected in both of the secondary (composite) large B-cell lymphomas. In the composite case with nodular lymphocyte predominant Hodgkin lymphoma, rare large cells in this adjacent nodular Hodgkin component were noted to have extra nonrearranged 2p23 loci consistent with extra copies of chromosome 2 in the neoplastic cells. Table 3 shows a summary of the results of the tests of statistical significance. In all study cases, extra copies of chromosome 2 were significantly associated with anaplastic morphology (P ¼ 0.004), without any significant association with the abovementioned WHO diagnostic categories (P ¼ 0.131), B-or T/null cell phenotype (P ¼ 0.315), CD30 positivity (P ¼ 1.000), or with the sex of the patient (P ¼ 0.250). Extra copies of chromosome 2 were not associated with ALK1 positivity by immunohistochemistry (P ¼ 0.009) or rearranged 2p23 ALK gene loci (P ¼ 0.009).
Statistical Analysis
In contrast, rearranged 2p23 ALK gene loci were invariably associated with ALK1 immunopositivity (Po0.001), and showed significant association with the above-mentioned diagnostic categories (P ¼ 0.016). The rearranged 2p23 loci were not significantly associated with anaplastic morphology (P ¼ 1.000), B-or T/null cell phenotype (P ¼ 0.088), and CD30 expression (P ¼ 1.000).
Discussion
Karyotypic abnormalities in lymphomas are generally much more complex as compared with leukemias. 29 These complex karyotypes include secondary abnormalities that are less specific than the primary abnormality, and are believed to reflect clonal evolution during tumor progression. 30 When a cytogenetic anomaly, such as the NPM-ALK gene translocation in t(2;5)(p23;q35) is the only change within neoplastic cells, it is thought to play a fundamental role in the initiation of the neoplastic process. While the NPM-ALK gene translocation is a necessary but insufficient event in the genesis of ALK þ ALCL, [31] [32] [33] little is known about the secondary cytogenetic or molecular genetic changes that lead to either cellular transformation in ALK þ ALCL or to ALKÀ systemic or cutaneous ALCL. 34 We observed extra copies of chromosome 2 as a recurring abnormality in all ALKÀ primary systemic ALCL (n ¼ 5) and 70% cutaneous ALCL (n ¼ 7) by FISH performed on paraffin-embedded tissue sections. Two ALCL recurrences examined were similar to their primary biopsies, indicating that increased copy number of chromosome 2 is not a random event in ALCL. This increased copy number of chromosome 2 in ALCL is most likely due to trisomy 2 since extra copies of chromosome 10 were absent in all but one case. We do not know whether this aberration is involved in initiation or progression of ALKÀ ALCL; it would be of interest to know the entire chromosomal constitution in our cases. In either situation, the present findings of trisomy 2 in the secondary B-cell lymphomas suggest that this aberration is not specific to ALCL and may represent a general secondary cytogenetic change in lymphomas. Extra copies of chromosome 2 are not uncommon in lymphomas, and have been reported in Hodgkin and non-Hodgkin lymphomas of B and T phenotype, 34 strengthening the idea that trisomy 2 may be a secondary cytogenetic aberration in ALCL.
Our study suggests that extra copies of chromosome 2 may be used as an additional marker to distinguish ALKÀ and ALK þ ALCL, since none of our ALK þ cases showed trisomy 2. A review of the literature identifies additional copies of chromosome 2 in four systemic ALCL cases, which include three ALK þ cases with variant translocations, and in two cutaneous ALCL cases, but they appear to be extremely rare in ALCL with the t(2;5) translocation. 34 We do not know whether there is a biological property that is inherent to ALK þ lymphomas that prevents duplication of chromosome 2. Whatever the mechanism, while trisomy 2 does not appear to be a frequent secondary event in the pathogenesis of ALK þ ALCL, it is a common finding in ALKÀ lymphomas with anaplastic morphology.
Two recent studies examined genomic alterations in primary cutaneous and systemic ALKÀ ALCL by comparative genomic hybridization. 35, 36 Firstly, Mao et al 35 have reported oncogene copy number gains that include the REL (2p13p12) and MYC-N (2p24.1) genes in six (75%) and four (50%) of their cutaneous ALCL cases, respectively. Secondly, in a study of Tcell lymphomas, Zettl et al 36 found imbalances of chromosome 2 in five (29%) nodal/systemic ALCL In conclusion, trisomy 2 occurs frequently in ALKÀ lymphomas with anaplastic morphology, including primary systemic ALKÀ and primary cutaneous ALCL. Whether it represents a primary or a secondary cytogenetic aberration in the clonal evolution of ALKÀ ALCL cannot be determined from this study. Additional studies beyond the scope of the current study would be required to elucidate the underlying molecular mechanism(s), and to ascertain the significance of trisomy 2 in the pathogenesis of this heterogeneous group of lymphomas.
